CAR T-CELLS COMPRISING AN ANTI CD33, AN ANTI CLL1 AND AT LEAST ONE FURTHER CAR ANTI CD123 AND/OR FTL3

1 - 29 . (canceled)

30 . A domain antibody (dAb) which binds CD123 and comprises the following complementarity determining regions (CDRs):

(i)

(SEQ ID No. 24)

CDR1 - GRSINTYA,

(SEQ ID No. 25)

CDR2 - INYNSRYT,

(SEQ ID No. 26)

CDR3 - AATSYYPTDYDVASRVATWPS;

(ii)

(SEQ ID No. 27)

CDR1 - GISLNA,

(SEQ ID No. 28)

CDR2 - IKIGGVS,

(SEQ ID No. 29)

CDR3 - NTYPPYLNGMDY;

(iii)

(SEQ ID No. 30)

CDR1 - GRSFNTDA,

(SEQ ID No. 31)

CDR2 - ISWDGTRT,

(SEQ ID No. 32)

CDR3 - AAEPQKAWPIGTSAAGFRS;

(iv)

(SEQ ID No. 33)

CDR1 - GSSISV, 

(SEQ ID No. 34)

CDR2 - ISWSDGNT,

(SEQ ID No. 35)

CDR3 - AVEPRGWPKGHRY;

(v)

(SEQ ID No. 36)

CDR1 - GSSFSINV,

(SEQ ID No. 37)

CDR2 - ISWSDGST,

(SEQ ID No. 38)

CDR3 - AVEPRGWPKGHRY;

or

(vi)

(SEQ ID No. 39)

CDR1 - GSIFRINA,

(SEQ ID No. 40)

CDR2 - VNWIGGTT,

(SEQ ID No. 41)

CDR3 - SATDKGGSSRY.

31 . A dAb according to claim 30 which comprises one of the sequences shown as SEQ ID NO: 42, 43, 44, 45, 46 or 47.

32 . A chimeric antigen receptor (CAR) which has an antigen binding domain comprising a dAb according to claim 30 .

33 . A chimeric antigen receptor (CAR) which has an antigen binding domain comprising a dAb according to claim 31 .

34 . A nucleic acid sequence encoding a dAb according to claim 30 or encoding a CAR comprising a dAb according to claim 30 .

35 . A vector comprising a nucleic acid sequence according to claim 34 .

36 . A cell which expresses a CAR which has an antigen binding domain comprising a dAb according to claim 30 .

37 . A method for making a cell which comprises the step of transducing or transfecting a cell with a vector according to claim 35 .

38 . A pharmaceutical composition comprising a plurality of cells according to claim 36 .

39 . A method for treating cancer which comprises the step of administering a pharmaceutical composition according to claim 38 to a subject.

40 . A method according to 39 , wherein the cancer is acute myeloid leukemia (AML).

41 . A domain antibody (dAb) which binds CLL-1 and comprises the following complementarity determining regions (CDRs):

(i)

(SEQ ID NO: 48)

CDR1 - GFTFGNHD,

(SEQ ID NO: 49)

CDR2 - IDSGGNVI,

(SEQ ID NO: 50)

CDR3 - ATDLDSGAESLESVY;

(ii)

(SEQ ID NO: 51)

CDR1 - GFAFGSAD,

(SEQ ID NO: 52)

CDR2 - IDSGGNTQ,

(SEQ ID NO: 53)

CDR3 - TDLDPTTDSLENVY;

(iii)

(SEQ ID NO: 54)

CDR1 - GRTFSAYF,

(SEQ ID NO: 55)

CDR2 - INWNGDSS,

(SEQ ID NO: 56)

CDR3 - AADTHGAVGLGSERLYDY;

(iv)

(SEQ ID NO: 57)

CDR1 - GIGVSSTG,

(SEQ ID NO: 58)

CDR2 - IDRDGTT,

(SEQ ID NO: 59)

CDR3 - TVVGDYY;

(v)

(SEQ ID NO: 60)

CDR1 - GFIFGNYD,

(SEQ ID NO: 61)

CDR2 - ISSGGNDI,

(SEQ ID NO: 62)

CDR3 - AADLDPGTDSLDNIH;

or

(vi)

(SEQ ID NO: 63)

CDR1 - GFTLDYYA,

(SEQ ID NO: 64)

CDR2 - ISSSDGST,

(SEQ ID NO: 65)

CDR3 - AEAVYYAGVCVAMYDS.

42 . A dAb according to claim 41 which comprises one of the sequences shown as SEQ ID NO: 66, 67, 68, 69, 70 or 71.

43 . A chimeric antigen receptor (CAR) which has an antigen binding domain comprising a dAb according to claim 41 .

44 . A chimeric antigen receptor (CAR) which has an antigen binding domain comprising a dAb according to claim 41 .

45 . A nucleic acid sequence encoding a dAb according to claim 41 or encoding a CAR comprising a dAb according to claim 41 .

46 . A vector comprising a nucleic acid sequence according to claim 45 .

47 . A cell which expresses a CAR which has an antigen binding domain comprising a dAb according to claim 41 .

48 . A method for making a cell which comprises the step of transducing or transfecting a cell with a vector according to claim 46 .

49 . A pharmaceutical composition comprising a plurality of cells according to claim 47 .

50 . A method for treating cancer which comprises the step of administering a pharmaceutical composition according to claim 49 to a subject.

51 . A method according to 50 , wherein the cancer is acute myeloid leukemia (AML).